

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA

SERGIO VAZQUEZ, Individually and on
Behalf of All Others Similarly Situated,
Plaintiff,
v.
MASIMO CORPORATION, JOSEPH
KIANI, MICAH YOUNG, BILAL
MUHSIN, AND ELI KAMMERMAN,
Defendants.

Case No.: 3:23-cv-01546-L-DEB

**ORDER GRANTING IN PART AND
DENYING IN PART DEFENDANTS'
MOTION TO DISMISS**

[ECF No. 38]

In this putative securities class action, Lead Plaintiffs Boston Retirement System (“BRS”), Central Pennsylvania Teamsters Pension Fund – Defined Benefit Plan (the “CPTPF Defined Benefit Plan”), and Central Pennsylvania Teamsters Pension Fund – Retirement Income Plan 1987 (the “CPTPF Retirement Plan”) (collectively, “Plaintiffs” or “Lead Plaintiffs”) allege that Defendants Masimo Corporation (“Masimo”), Joseph Kiani, Micah Young, Bilal Muhsin, and Eli Kammerman (collectively, “Defendants”) made repeated material misrepresentations and concealed material facts related to Masimo’s core healthcare unit and its non-healthcare unit following the Company’s acquisition of consumer audio firm, Sound United. Defendants here filed the instant motion to dismiss the complaint, arguing that Plaintiffs failed to plead falsity and failed

1 to plead a strong inference of scienter. (ECF No. 38.) Plaintiffs filed an opposition (ECF
2 No. 42), and Defendants replied (ECF No. 44). The Court decides the matter on the
3 papers submitted without oral argument. *See* Civ. L.R. 7.1(d.1). For the reasons which
4 follow, Defendant’s motion to dismiss is GRANTED IN PART and DENIED IN PART.

5 **I. BACKGROUND¹**

6 **1. The Parties**

7 Lead Plaintiffs purchased shares of Masimo common stock during the class period
8 and were allegedly damaged by misrepresentations and omissions made by Defendants
9 about the state of Masimo. Lead Plaintiffs seeks to represent a putative class of all
10 persons and entities, other than those excluded by definition, that purchased or otherwise
11 acquired the publicly traded common stock of Masimo during the period from May 4,
12 2022, through August 8, 2023, inclusive (the “Class Period”).

13 Defendant Masimo Corporation is a Delaware corporation with its headquarters
14 located at 52 Discovery, Irvine, California 92618. Defendant Joseph Kiani (“Kiani”)
15 founded Masimo in 1989. Kiani was, at all relevant times, Masimo’s founder, CEO, and
16 Chairman. Defendant Micah Young (“Young”) was, at all relevant times, Masimo’s
17 CFO. Defendant Bilal Muhsin (“Muhsin”) was, at all relevant times, Masimo’s COO.
18 Prior to his role as COO, Muhsin was the EVP of Engineering, Marketing, and
19 Regulatory Affairs, following several Engineering leadership roles in his more than
20 twenty years at the Company. Defendant Eli Kammerman (“Kammerman”) has served
21 as Vice President, Business Development and Investor Relations since 2009.

22 **2. Masimo Corporation’s Business and Acquisition of Sound United**

23 According to Plaintiffs, Masimo is a global medical technology company that
24 develops, manufactures, and markets a variety of non-invasive monitoring technologies.
25

26
27 ¹ Reviewing Defendants’ motion to dismiss, the Court accepts as true all facts alleged in the
28 complaint and construes them in the light most favorable to Plaintiff. *See Snyder & Assocs. Acquisitions LLC v. United States*, 859 F.3d 1152, 1157 (9th Cir. 2017). Unless otherwise noted, all facts are taken from the amended complaint. (ECF No. 28.)

1 Masimo was founded by Defendant Kiani in 1989 and remained private, under Kiani's
2 leadership, for eighteen years until going public on August 8, 2007. Currently, Masimo
3 employs over 6,000 employees across twenty-seven offices. Prior to 2022, Masimo's
4 business solely focused on its products related to healthcare. Masimo developed and sold
5 patient-monitoring technologies, hospital automation and connectivity solutions, remote
6 monitoring devices, and consumer health products. Masimo's most successful and well-
7 known product is its SET pulse oximeter and is most often seen as a version that attaches
8 to a patient's fingertip to retrieve data. Masimo describes the SET pulse oximetry
9 product line, which measures through motion and low perfusion arterial blood oxygen
10 saturation and pulse rate monitoring, as its "core business." Masimo sells its healthcare
11 products to hospitals, emergency medical providers, home care providers, physician
12 offices, veterinarians, long-term care facilities, and consumers through the Company's
13 direct sales force, distributors, and original equipment manufacturer partners.

14 Masimo acquired a consumer audio company called Sound United in 2022 in an
15 all-cash deal for \$1.025 billion, the largest deal in Masimo's history. Sound United had
16 never been involved in health care products. In a company press release dated February
17 15, 2022, Kiani stated that "Masimo shares Sound United's commitment to providing
18 innovative, best-in-class products and experiences, with a relentless focus on improving
19 the consumer experience." In the same press release, Kiani touted the purported benefits
20 of the acquisition to Masimo's business including Sound United's direct-to-consumer
21 relationships and product distribution expertise.

22 As currently made up, Masimo is a technology company that is divided into two
23 discrete segments: (1) healthcare; and (2) non-healthcare, consisting of what was
24 formerly Sound United. According to Masimo's 2023 Form 10-K, its "healthcare
25 business develops, manufactures and markets a variety of noninvasive patient monitoring
26 technologies, hospital automation and connectivity solutions, remote monitoring devices
27 and consumer health products." Masimo's "non-healthcare consumer audio business
28

1 develops, manufactures, markets, sells and licenses premium and luxury audio, and
2 related integration technologies.”

3 **3. Alleged Fraud²**

4 The Class Period in this case begins after the acquisition of Sound United by
5 Masimo. Plaintiffs allege that “Masimo struggled to integrate Sound United into
6 Masimo” and that “Sound United’s accounting practices fell below the standards required
7 for a public company and utilized ‘plugs’ to ensure that reported financial figures met
8 expectations.” (ECF No. 28 at 27.) Furthermore, Plaintiffs allege troubles in Masimo’s
9 healthcare segment: “Masimo’s healthcare segment struggled to sell new products as the
10 marketplace refused to adopt their technologies and new long-term contracts, as the
11 Company’s inventory of single-use sensors ballooned.” (*Id.*)

12 **4. Masimo Updates Guidance**

13 Plaintiffs allege that the truth began to emerge on July 17, 2023, when “Masimo
14 issued a preannouncement of its second quarter 2023 earnings and revealed a substantial
15 cut to its full-year guidance due to weaknesses in both its healthcare and SU segments,
16 including a decline in single-patient use sensor sales driven in part by ‘[e]levated sensor
17 inventory levels [] due to discounting’ and a ‘decline in demand [for] premium and
18 luxury audio categories.’” (ECF No. 42 at 18.) The stock declined over the next two
19 days of trading from \$147.16 per share on July 17, 2023 to a close of \$112.28 per share
20 on July 19, 2023. (*Id.* at 19.) Further, “on August 8, 2023, after the market closed,
21 Masimo released its second quarter 2023 earnings release detailing consolidated revenue
22 of \$455.3 million, including a 21% decline in healthcare and a 17% percent decline in
23 non-healthcare, and Defendant Kiani announced a \$100 million reduction in expenses
24 due to the revenue shortfall.” (*Id.*) This news caused Masimo’s stock to fall from
25 \$120.00 per share to \$117.96 per share. (*Id.*)

26
27
28 ² As relevant, each specific incident of alleged fraud is discussed below.

II. LEGAL STANDARDS

1. Motion to Dismiss

Pursuant to Federal Rule of Civil Procedure 12(b)(6), a defendant may move to dismiss an action for failure to state a claim upon which relief may be granted. Because Plaintiffs have brought their claims as a federal securities fraud action, Plaintiffs are not subject to the notice pleading standards under Federal Rule of Civil Procedure 8(a)(2), which require litigants to provide “a short and plain statement of the claim showing that the pleader is entitled to relief.” Instead, Plaintiffs must “meet the higher, [more] exacting pleading standards of Federal Rule of Civil Procedure 9(b) and the Private Securities Litigation Reform Act (PSLRA).” *Or. Pub. Emp. Ret. Fund v. Apollo Group Inc.*, 774 F.3d 598, 603–04 (9th Cir. 2014) (“*Apollo Group*”).³

Under Federal Rule of Civil Procedure 9(b), “[i]n alleging fraud or mistake, a party must state with particularity the circumstances constituting fraud or mistake.” Plaintiffs must include “an account of the time, place, and specific content of the false representations” at issue. *Swartz v. KPMG LLP*, 476 F.3d 756, 764 (9th Cir. 2007). Rule 9(b)’s particularity requirement “applies to all elements of a securities fraud action.” *Apollo Group*, 774 F.3d at 605. “PSLRA imposes additional specific pleading requirements, including requiring plaintiffs to state with particularity both the facts constituting the alleged violation and the facts evidencing scienter.” *In re Rigel Pharmaceuticals, Inc. Sec. Litig.*, 697 F.3d 869, 877 (9th Cir. 2012). In order to properly allege falsity, “a securities fraud complaint must ... specify each statement alleged to have been misleading, [and] the reason or reasons why the statement is misleading.” *Id.* In addition, in order to “adequately plead scienter under the PSLRA, the complaint must state with particularity facts giving rise to a strong inference that the defendant acted with the required state of mind.” *Id.*

³ Unless stated otherwise, internal ellipses, brackets, citations, and quotation marks are omitted from citations.

For purposes of ruling on a Rule 12(b)(6) motion, the Court “accept[s] factual allegations in the complaint as true and construe[s] the pleadings in the light most favorable to the nonmoving party.” *Manzarek v. St. Paul Fire & Marine Ins. Co.*, 519 F.3d 1025, 1031 (9th Cir. 2008). Nonetheless, the Court is not required to “assume the truth of legal conclusions merely because they are cast in the form of factual allegations.” *Fayer v. Vaughn*, 649 F.3d 1061, 1064 (9th Cir. 2011) (quoting *W. Mining Council v. Watt*, 643 F.2d 618, 624 (9th Cir. 1981)). Mere “conclusory allegations of law and unwarranted inferences are insufficient to defeat a motion to dismiss.” *Adams v. Johnson*, 355 F.3d 1179, 1183 (9th Cir. 2004). Furthermore, “a plaintiff may plead [him]self out of court” if he “plead[s] facts which establish that he cannot prevail on his ... claim.” *Weisbuch v. Cty. of L.A.*, 119 F.3d 778, 783 n.1 (9th Cir. 1997) (quoting *Warzon v. Drew*, 60 F.3d 1234, 1239 (7th Cir. 1995)).

2. Leave to Amend

“If a complaint is dismissed for failure to state a claim, leave to amend should be granted ‘unless the court determines that the allegation of other facts consistent with the challenged pleading could not possibly cure the deficiency.’” *DeSoto v. Yellow Freight Sys., Inc.*, 957 F.2d 655, 658 (9th Cir. 1992) (quoting *Schreiber Distrib. Co. v. Serv-Well Furniture Co.*, 806 F.2d 1393, 1401 (9th Cir. 1986)). “A district court does not err in denying leave to amend where the amendment would be futile.” *Id.*

III. JUDICIAL NOTICE AND INCORPORATION BY REFERENCE

Defendants request the court consider 14 exhibits, totaling 190 pages, through judicial notice and incorporation by reference. (ECF No. 38-3 (Request for Judicial Notice); ECF Nos. 38-5 to 38-18 (Exhibits 1-14).) These documents encompass: (1) Masimo’s earnings call transcripts (Exs. 2-3, 8, 10, 12-13); (2) Masimo’s presentation transcripts at investor conferences (Exs. 6, 9, 14); (3) Masimo’s quarterly reports that were filed on SEC Form 10-Qs (Exs. 4-5); (4) Masimo’s annual reports that were filed on SEC Form 10-Ks (Exs. 1, 11); and (5) certain SEC Form 4s that were filed by Defendant Kiani (Ex. 7). Plaintiffs oppose the request for consideration under the incorporation by

1 reference and judicial notice doctrines, arguing that “Defendants abuse the judicial notice
2 and incorporation-by-reference doctrines by offering documents as exhibits to submit
3 their alternative version of the facts for purposes of disputing the Complaint’s well-pled
4 factual allegations.” (ECF No. 43 at 3.)

5 Generally, a district court may not consider material outside the pleadings when
6 considering a Rule 12(b)(6) motion to dismiss. *See Lee v. City of Los Angeles*, 250 F.3d
7 668, 688 (9th Cir. 2001). Otherwise, the motion is converted into one for summary
8 judgment. *See Fed. R. Civ. P. 12(d)*. There are two relevant exceptions to this rule:
9 “documents incorporated into the complaint by reference, and matters of which a court
10 may take judicial notice.” *Tellabs, Inc. v. Makor Issues & Rts., Ltd.*, 551 U.S. 308, 322
11 (2007).

12 A court may take judicial notice of a fact “that is not subject to reasonable dispute
13 because it: (1) is generally known within the trial court's territorial jurisdiction; or (2) can
14 be accurately and readily determined from sources whose accuracy cannot reasonably be
15 questioned.” Fed. R. Evid. 201(b).

16 Under the incorporation by reference doctrine, while the mere mention of the
17 existence of a document is insufficient to incorporate the contents of a document, the
18 document is incorporated when its contents are described and the document is integral to
19 the complaint. *Tunac v. United States*, 897 F.3d 1197, 1207 n.8 (9th Cir. 2018). The
20 incorporation by reference doctrine “prevents plaintiffs from selecting only portions of
21 documents that support their claims, while omitting portions of those very documents that
22 weaken—or doom—their claims.” *Khoja v. Orexigen Therapeutics, Inc.*, 899 F.3d 988,
23 1002 (9th Cir. 2018). However, it “is not a tool for defendants to short-circuit the
24 resolution of a well-pleaded claim,” for example, by attempting to use a document that is
25 not mentioned in the complaint “to insert their own version of events into the complaint
26 to defeat otherwise cognizable claims.” *See id.* at 1002-03. Although a court may
27 assume the contents of an incorporated document are true for the purposes of a motion to
28 dismiss, “it is improper to assume the truth of an incorporated document if such

1 assumptions only serve to dispute facts stated in a well-pleaded complaint.” *See id.* at
2 1003.

3 The Ninth Circuit has identified a “concerning pattern in securities cases”: parties
4 “exploiting these procedures improperly to defeat what would otherwise constitute
5 adequately stated claims at the pleading stage.” *Id.* at 998. Although these doctrines “do
6 have roles to play at the pleading stage,” the court noted that the “overuse and improper
7 application of judicial notice and the incorporation-by-reference doctrine ... can lead to
8 unintended and harmful results,” including “premature dismissals of plausible claims that
9 may turn out to be valid after discovery.” *See id.* The court specifically referenced the
10 “alluring temptation” defendants face “to pile on numerous documents to their motions to
11 dismiss to undermine the complaint.” *Id.*

12 All the documents requested to be considered by Defendants are properly
13 incorporated by reference, subject to judicial notice, or both. However, the documents
14 may not be used to dispute well-pleaded facts.

15 SEC filings are the proper subjects of judicial notice as they are not subject to
16 reasonable dispute. *See Dreiling v. American Exp. Co.*, 458 F.3d 942, 946 n.2 (9th Cir.
17 2006). Accordingly, the Court will grant Defendants’ request to take judicial notice of
18 the SEC Form 10-Qs, 10-Ks, and 4s (Exs. 1, 4, 5, 7, 11). However, the Court does not
19 consider the contents of the documents for the truth of the matters asserted therein. *See*
20 *In re Bare Escentuals, Inc. Sec. Litig.*, 745 F. Supp. 2d 1052, 1067 (N.D. Cal. 2010)
21 (granting defendants’ request to take judicial notice of SEC filings but specifying that
22 they will not “where inappropriate” be considered for the truth of the matter asserted).
23 Further, the Masimo earning call transcripts (Exs. 2-3, 8, 10, 12-13) and Masimo
24 Presentation transcripts (Exs. 6, 9, 14) are properly considered by judicial notice. *See*
25 *Mallen v. Alphatec Holdings, Inc.*, 861 F. Supp. 2d 1111, 1122–23 n.5 (S.D. Cal. 2012)
26 (Press releases and transcripts of conference calls properly subject to judicial notice when
27 not subject to reasonable dispute).
28

1 Additionally, Exhibits 1-6, 8-10, and 12-14 are incorporated by reference in the
2 Complaint. The complaint quotes and references these documents extensively, including
3 Masimo's Form 10-Q, Form 10-K, earnings conference calls, and investor presentation
4 during the class period. (ECF No. 28 at ¶¶ 77, 81, 90, 256, 260- 72, 277-88, 291-96, 299-
5 306, 320-22, 326-34, 337-339, 341-43, 354-59, 371.) The contents of these documents
6 may not be used to dispute well-pleaded allegations in the Complaint; however, the
7 documents may be properly used to provide full context to documents referred to by
8 Plaintiffs. *See Khoja*, 899 F.3d at 1002 (The incorporation by reference doctrine may not
9 be used for defendants "to insert their own version of events into the complaint to defeat
10 otherwise cognizable claims" but may be used to "prevent[] plaintiffs from selecting only
11 portions of documents that support their claims, while omitting portions of those very
12 documents that weaken—or doom—their claims.").

13 **IV. DISCUSSION**

14 Plaintiffs allege two causes of action: (1) violation of § 10(b) of the Exchange Act
15 and Rule 10b-5 against all Defendants, and (2) violation of § 20(a) of the Exchange Act
16 against the Individual Defendants. The Court addresses each cause of action in turn.

17 **1. Violation of § 10(b) of the Exchange Act and Rule 10b-5**

18 Section 10(b) of the Exchange Act declares it "unlawful ... to use or employ, in
19 connection with the purchase or sale of any security registered on a national securities
20 exchange ... any manipulative or deceptive device or contrivance in contravention of such
21 rules and regulations as the [SEC] may prescribe as necessary or appropriate in the public
22 interest or for the protection of investors." 15 U.S.C. § 78j(b). "Rule 10b-5 implements
23 Section 10(b) by making it unlawful '[t]o make any untrue statement of a material fact or
24 to omit to state a material fact necessary in order to make the statements made, in the
25 light of the circumstances under which they were made, not misleading.'" *Glazer Cap.*
26 *Mgmt., L.P. v. Forescout Techs., Inc.*, 63 F.4th 747, 764 (9th Cir. 2023) (quoting 17
27 C.F.R. § 240.10b-5(b)). "To plead a claim under section 10(b) and Rule 10b-5, Plaintiff
28 must allege: (1) a material misrepresentation or omission; (2) scienter; (3) a connection

1 between the misrepresentation or omission and the purchase or sale of a security; (4)
2 reliance; (5) economic loss; and (6) loss causation.” *Apollo Group*, 774 F.3d at 603.
3 Defendants argue that Plaintiffs’ complaint should be dismissed because (1) the
4 complaint fails to allege a false or misleading statement; and (2) the complaint fails to
5 allege scienter. Defendants do not, at this time, contest a connection between the
6 misrepresentation or omission and the purchase or sale of a security, reliance, economic
7 loss, or loss causation.

8 **a. Material Misrepresentation or Omission**

9 Section 10(b) and Rule 10b-5 require a plaintiff to show that the defendant made a
10 statement that was false or misleading as to a material fact. *Basic Inc. v. Levinson*, 485
11 U.S. 224, 238 (1988). “Falsity is alleged when a plaintiff points to defendant’s
12 statements that directly contradict what the defendant knew at that time.” *Khoja*, 899 F.3d
13 at 1008. “Even if a statement is not false, it may be misleading if it omits material
14 information.” *Id.* at 1008–09. “[A] statement is misleading if it would give a reasonable
15 investor the ‘impression of a state of affairs that differs in a material way from the one
16 that actually exists.’ ” *Retail Wholesale & Dep’t Store Union Loc. 338 Ret. Fund v.*
17 *Hewlett-Packard Co.*, 845 F.3d 1268, 1275 (9th Cir. 2017) (alteration in original)
18 (quoting *Berson v. Applied Signal Tech., Inc.*, 527 F.3d 982, 985 (9th Cir. 2008)).
19 “Courts apply the objective standard of a ‘reasonable investor’ to determine whether a
20 statement is misleading.” *In re Splunk Inc. Sec. Litig.*, 592 F. Supp. 3d 919, 932 (N.D.
21 Cal. 2022). There is no requirement of a “strong inference of fraud.” *Glazer Cap.*
22 *Mgmt., L.P.*, 63 F.4th at 766. Instead, “[f]alsity is subject to a particularity requirement
23 and the *reasonable inference* standard of plausibility set out in *Twombly* and *Iqbal*[.]”
24 *Id.* (emphasis in original).

25 Plaintiffs allege that 40 statements contain material misrepresentations or
26 omissions regarding Masimo’s historical financial performance, Masimo’s prospects for
27 future performance, the Sound United acquisition, and Masimo’s disclosure controls.
28 The Court need not exhaustively, at the motion to dismiss stage, determine if each

1 statement identified is a material misrepresentation or omission. If Plaintiffs can plead a
2 single material misrepresentation or omission, they are able to defeat the motion to
3 dismiss on this ground. *See In re: Bofi Holding, Inc. Sec. Litig.*, No.
4 315CV02324GPCSKS, 2016 WL 5390533, at *8 (S.D. Cal. Sept. 27, 2016) (“Plaintiffs
5 need only plead a single materially false misrepresentation to survive a motion to
6 dismiss.”); *see also Feyko v. Yuhe Intern., Inc.*, 2013 WL 816409, at *4 n.2 (C.D. Cal.
7 Mar. 5, 2013) (same).

8 **i. Past Performance Statements**

9 Plaintiffs allege that Defendants made statements about past financial
10 performances that were false or materially misleading because they failed to “disclos[e]
11 material information about how that performance was achieved.” (ECF No. 42 at 21.)
12 Plaintiffs allege that various statements made by Defendants were false, including
13 Defendant Kiani’s statement on May 3, 2022 that Masimo “experienced strong demand
14 for [its] products” in the first quarter of 2022, Defendant Young’s statement on May 3,
15 2022 that, but for supply chain issues, “[Masimo] would have exceeded [its] revenue and
16 earnings expectations,” and Defendant Muhsin’s statement on December 13, 2022 that
17 the SET oximetry business was “continuing to win business from [its] competitors.”
18 (ECF No. 28 at ¶¶ 257, 264, 310.)

19 According to Plaintiffs, these statements are false and misleading because they are
20 inconsistent with “internal information known and concealed by Defendants throughout
21 the Class Period, as described by several Confidential Witnesses (“CWs”) from different
22 areas of the Company and from different geographic regions.” (ECF No. 42 at 22.)
23 Specifically, Plaintiffs allege that Defendants failed to include the necessary information
24 that “(i) [Masimo] had begun offering larger discounts to customers to take excess
25 product (sometimes above the amount in customer contracts or orders) leading to
26 overstuffed inventories at Masimo’s customers; and (ii) this deep discounting, while not
27 improper on its own, was severely cannibalizing future product demand,” and that “the
28 healthcare sales team was experiencing pushback from customers unwilling to sign new

1 multi-year contracts and unwilling to order Masimo healthcare devices other than the
2 core SET pulse oximetry devices.”⁴ (*Id.* at 21-22.)

3 First, Plaintiffs have failed to show, even assuming Defendants failed to disclose
4 discounts, there was anything improper about this practice or that it led to Defendants’
5 statements being materially false or misleading. *See, e.g., City of Sunrise Firefighters’*
6 *Pension Fund v. Oracle Corp.*, 2019 WL 6877195, at *11, n.7 (N.D. Cal. Dec. 17, 2019)
7 (“Securities laws’ purpose is not to police customer discounts.”). Further, Plaintiff’s
8 allegations are insufficiently plead as they fail to meet the particularity requirements for a
9 securities action. *Apollo Group*, 774 F.3d at 605. Plaintiffs allege that “[d]uring the
10 Class Period, the Company had begun offering larger ‘discounts’ to customers,” but fail
11 to state when, or how much, these discounts are. Plaintiffs rely on CW-2, who states that
12 “in 2022” he was directed to “offer discounts” to hospital customers. (ECF No. 28 at ¶¶
13 248, 253.) These allegations fall far short of the necessary particularity to show that
14 Defendants’ statements were false or misleading about demand simply because they did
15 not disclose discounting practices.

16 Second, Plaintiffs’ allegations regarding Defendants’ difficulties selling “Masimo
17 devices outside of the core SET pulse oximetry devices” does not render Defendants
18 statements materially misleading or false as the challenged statements make no mention
19 of Masimo’s ability to sell its non-core products. (*See* ECF No. 28 at ¶ 268(c).)
20
21
22

23
24 ⁴ In Plaintiff’s complaint, he also alleges that the past performance statements were false and
25 materially misleading due to Defendants utilizing accounting “plugs” and Sound United experiencing
26 “ballooning inventory.” However, Plaintiff only addresses discounting affecting future demand and
27 pushback from customers on signing multi-year contracts on non-core SET pulse oximetry devices in his
28 opposition to the motion to dismiss. Accordingly, Plaintiff waives any argument that Defendants
utilizing accounting “plugs” and Sound United experiencing “ballooning inventory” as reasons why the
past performance statements are false or misleading. *See Allen v. Dollar Tree Stores, Inc.*, 475 F.
App’x. 159, 159 (9th Cir. 2012) (affirming district court’s dismissal of plaintiff’s claims in which
plaintiff’s “opposition to the motion to dismiss failed to respond to [the defendant’s] argument.”).

1 Third, Plaintiffs’ have included no facts that show how Defendant Muhsin’s
2 statement on December 13, 2022, that the SET oximetry business was “continuing to win
3 business from [its] competitors” is materially misleading or false.

4 Finally, Plaintiffs’ allegations regarding “Masimo’s healthcare sales team []
5 encountering serious pushback from customers” for the “Company’s new five-year
6 contracting terms because customers did not want be locked into a contract for that long,”
7 also do not render Defendants statements materially misleading or false. Plaintiffs do not
8 explain how customers unwillingness to commit to five-year contracts makes statements
9 about Masimo’s past performance false. Further, this statement about “Masimo’s
10 healthcare sales team” stems from a single sales rep who worked as a “Territory Manager
11 for Alternate Care,” who stated that in 2021 (which predates the class period),
12 “respiratory therapists, nurse managers, and purchasing managers were reluctant to
13 commit to 5-year deals.” (*Id.* at ¶¶ 235-246.) Plaintiffs cannot rely on a single sales rep
14 who encountered sales difficulties to show that Defendants’ company wide past
15 performance statements were false or materially misleading. Accordingly, Masimo’s past
16 performance statements are not adequately alleged to be false or misleading.

17 **ii. Future Performance Statements**

18 Plaintiffs allege that “Defendants made false and misleading statements about
19 Masimo’s prospects for growth that were false and misleading due to improper
20 accounting practices, including ‘plugs’ at SU.”⁵ (ECF No. 42 at 22-23.) For example, in
21

22 ⁵ In Plaintiffs’ complaint, they also allege that the future performance statements were false and
23 materially misleading due to Defendants utilizing discounts and not reporting sales difficulties.
24 However, in Plaintiffs’ opposition to the motion to dismiss, they only discuss accounting and internal
25 control issues as the reason for why Masimo’s growth prospects were false. (*See* ECF No. 42 at 22-23.)
26 Plaintiffs’ only mention of discounts or sales difficulties is the final sentence of the section, when they
27 state that there was “declining demand for healthcare products, which were well documented internally,”
28 without any citations to the complaint. Further, Plaintiffs fail to respond to Defendants’ arguments that
any discounting or declining demand was not relevant to the challenged statements. (*See* ECF No. 38-1
at 21-24.) Accordingly, Plaintiffs waive their arguments that discounting practices or sales difficulties
show that Defendants’ future performance statements were false or misleading. *See Allen*, 475 F. App’x.
at 159.

1 Masimo’s Q2 2022 earnings press release, Masimo included guidance for the third
2 quarter of 2022 and full year of 2022, including “guidance for legacy Sound United of
3 \$195 million to \$215 million for the third quarter of 2022 and \$655 million to \$700
4 million for the full year 2022.” (ECF No. 28 at ¶ 274.) According to Plaintiffs:

5 Defendants knew or deliberately disregarded that the use of “plugs” at legacy
6 Sound United to balance and close its books manipulated and artificially inflated
7 the Company’s overall financial results. Indeed, each month, Sound United
8 recorded “plug” entries altering, among other things, Sound United’s cost of goods
9 sold and inventory because otherwise Sound United’s accounting records could not
10 be balanced. These monthly “plug” entries occurred in amounts up to \$14
11 million—well in excess of the Sound United financial statement materiality
12 threshold of \$2 million. As confirmed by former Sound United and Masimo
employees, the “plug” was a COGS credit that artificially inflated Sound United’s
margins with the offset going to inventory, the motive of which was to meet
forecasted numbers for non-healthcare/legacy Sound United.

13 (*Id.* at ¶ 276 (footnote omitted).)

14 Plaintiffs rely in part on CW-14, the “Vice President Finance & Global Controller
15 at Sound United from September 2021 until his departure from Masimo.” (*Id.* at ¶ 54.)
16 CW-14 stated that Defendant Young “personally sent directives to enter a cost of goods
17 sold credit with a debit to inventory that juiced the margins to ensure SU met its
18 forecasts.” (ECF No. 42 at 15 (citing ECF No. 28 at ¶ 161).) According to CW-14,
19 “Sound United was plugging as much as \$9 million a month into the books as part of the
20 closing process.” (ECF No. 28 at ¶ 162.) The “plugs” were “generally recorded as a
21 credit to Cost of Goods Sold (COGS) and a debit to Inventory,” and that the
22 “manipulation of Sound United’s financial close numbers continued after the Sound
23 United acquisition.” (*Id.*)

24 Defendants argue that Plaintiffs fail to allege falsity with particularity with respect
25 to the “plugs.” (ECF No. 44 at 12-13.) Defendants contend that CW-14 “explained his
26 ‘concerns’ to Masimo’s independent auditor, and they ‘signed off on the earnings
27 anyway,’ Opp. at 7, a concession that destroys all suggestion that Masimo made false
28

statements about financial performance.” (*Id.* at 13.) However, on a motion to dismiss, the Court does not weigh factual disputes and accepts well-pleaded facts that comply with the heightened pleading standards of the PSLRA and Federal Rule of Civil Procedure 9(b). *See Apollo Group Inc.*, 774 F.3d at 603–04. Here, Plaintiffs sufficiently allege with particularity that Masimo utilized “plugs,” that made their margins appear to be stronger than they were, and that as a result, at least one of Defendants forward-looking statements about legacy Sound United’s projected earnings was materially false or misleading.⁶ Accordingly, Plaintiffs meets their burden of alleging a false or misleading statement relating to the future performance statements.

iii. Sound Acquisition Statements

During the Class Period, Defendants made various statements about the process of integration between Masimo and Sound United. For example, Defendant Kiani in the first quarter earnings release on May 3, 2022, stated that Masimo was “deeply engaged in combined efforts [with Sound United] to generate some exciting new products launches in consumer health & wellness.” (ECF No. 28 at ¶ 257.) Defendant Young was asked about the status of the integration of Sound United into Masimo on November 15, 2022, at the Stifel Healthcare Conference and he stated “[t]he back office, we’ve been integrating more to the back office. That’s been driving some efficiencies there for us. We’re through the majority of the integration. So we still have some systems integrations that we need to work through, but it’s going very well so far.” (*Id.* at ¶ 304.) As part of the fourth quarter earnings press release on February 28, 2023, Defendant Kiani stated about the integration that “... we’ve already completed the integration and are working to

⁶ The Court need not consider every challenged statement as a Plaintiff only needs to sufficiently plead one false or misleading statement to proceed on this element. *See In re: Bofi Holding, Inc. Sec. Litig.*, No. 315CV02324GPCSKSC, 2016 WL 5390533, at *8 (S.D. Cal. Sept. 27, 2016) (“Plaintiffs need only plead a single materially false misrepresentation to survive a motion to dismiss.”). Defendants contend that other future performance statements are either protected under the PSLRA’s safe harbor provision or are protected opinions. As Plaintiff has adequately alleged at least one future performance statement, the Court does not consider whether other statements are protected under the PSLRA’s safe harbor provision or are protected opinions.

1 realize the tremendous potential of the hearables, wearables and telemonitoring markets
2 unlocked by our unique combination of healthcare and consumer technology
3 capabilities.” (*Id.* at ¶ 324.) Further, on the earnings call that same day, Kiani repeated
4 “we’ve already completed the integration of Sound United[.]” (*Id.* at ¶ 326.)

5 Plaintiffs allege that these statements about integration were materially false
6 because “Defendants had no roadmap or integration plan following the Sound United
7 acquisition and no integration plans were ever put in place throughout the Class Period”
8 and “[a]s a result of the lack of roadmap and integration plan, the two segments (Masimo
9 healthcare and legacy Sound United) remained almost completely segregated throughout
10 the Class Period.” (*Id.* at ¶ 259.)

11 In support of these allegations, Plaintiffs rely on CW-14 and CW-15, who was the
12 Vice President of Finance Transformation and Risk in Masimo’s legacy Sound United
13 segment from July 2022 to August 2023. (*Id.* at ¶ 54-55.) According to CW-14,
14 “following Masimo’s acquisition of Sound United, there was no intercompany
15 consolidation.” (*Id.* at ¶ 179.) According to CW-14, they “never observed any synergies
16 between the two companies during his time at Masimo nor were there any efforts to
17 integrate the two accounting groups. CW-14 recalled that there was ‘only’ a \$40,000
18 intracompany booking between legacy Sound United and healthcare by the time CW-14
19 left Masimo in August 2023, with \$80,000 or \$90,000 pending.” (*Id.*) Further, according
20 to CW-15, “there was ‘very little’ or no integration between Masimo and Sound United
21 from a finance standpoint and ‘less so’ from an IT and operations perspective. CW-15
22 added that during his tenure, there were never any common projects or synergies between
23 the two segments.” (*Id.* at 180.)

24 Defendants argue that these statements are not materially false. First, with regards
25 to Defendant Kiani’s statements in the first quarter earnings release on May 3, 2022, they
26 argue that these statements were not in relation to integration at all, but about new
27 products the combined companies were working to develop. (ECF no. 38-1 at 30.)
28 Defendants’ points to the earnings call transcript from this date, and the announcement of

1 products such as a biosensing watch and augmented hearing devices. (*Id.*) Second, they
2 argue that the challenged statements in November 2022 and February 2023 are not false.
3 Defendants characterize Plaintiff’s challenge to these statements being that Defendants
4 did not mention that Masimo’s healthcare business had begun offering discounts and was
5 encountering pushback on new contract terms, and because Kiani had fired Sound
6 United’s former CEO months before. (*Id.*) Further, they argue that CW-15’s allegations
7 are immaterial as Kiani said nothing about “finance” or “IT” or “operations” integration.
8 (*Id.*)

9 The Court finds that Plaintiffs have adequately alleged at least some of the
10 statements regarding integration as material misrepresentations. While Defendant
11 Kiani’s statement in the first quarter earnings release on May 3, 2022, shown in its full
12 context, likely relates to the products such as the biosensing watch and augmented
13 hearing devices and is not adequately alleged as a misrepresentation, the other statements
14 listed above are not similarly limited and plausibly relate to the integration of the two
15 businesses as a whole. Based on the confidential witness claims, Plaintiffs have
16 adequately alleged at the motion to dismiss stage that these statements are
17 misrepresentations, as large sections of the integration were still in the fledgling stages.
18 Especially in the context of a merger that was touted as Masimo being able to utilize
19 Sound United’s “direct-to-consumer relationships and product distribution expertise,”
20 Defendants’ broad comments on being through the “majority” of the integration and the
21 “completion” of the integration between the two companies is adequately alleged to be a
22 material misrepresentation when the Plaintiff has alleged that much of the integration
23 work had not been done and the two companies were acting independently. (*See* ECF
24 No. 28 at ¶ 67.) Accordingly, Plaintiffs meets their burden of alleging a false or
25 misleading statement relating to the Sound United Acquisition.

26 **iv. Internal Control Statements**

27 Plaintiffs challenge Masimo’s statement in four different Form 10-Q’s that, “[w]e
28 maintain disclosure controls and procedures that are designed to ensure that information

1 required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as
2 amended (the Exchange Act), is recorded, processed, summarized and reported within the
3 time periods specified in the Securities and Exchange Commission’s (SEC) regulations,
4 rules and forms and that such information is accumulated and communicated to our
5 management, including our CEO and Chief Financial Officer (CFO), as appropriate, to
6 allow for timely decisions regarding required disclosure.” (ECF No. 38 at ¶¶ 260, 287,
7 298, 341.)

8 According to Plaintiffs, this is misleading because Defendants “failed to disclose a
9 known and pervasive lack of internal controls and inadequate accounting practices that
10 hindered the integration, as well as SU’s operations.” (ECF No. 42 at 28.) However,
11 Plaintiffs concede in their complaint that Masimo is not required to provide disclosures
12 regarding Sound United’s “Effective internal control over financial reporting” (“ICFR”)
13 and “disclosure controls and procedures” (“DCP”) until one year after the acquisition.
14 (ECF No. 38 at ¶ 116.) Further, in the same 10-Q’s that Plaintiffs argue are misleading
15 for failing to disclose Sound United’s supposed internal control issues, Masimo states
16 that its internal-controls assessment “does not include Sound United.” (ECF No. 38-5 at
17 26.) Plaintiff fails to respond to Defendants’ argument that these statements were not
18 misleading on this ground. Plaintiffs contend that “misleading statements about the
19 strength of a company’s internal controls can be misleading.” (ECF No. 42 at 26.)
20 However, Plaintiffs fail to point out any statements that Defendants actually make about
21 Sound United’s internal controls. Accordingly, Masimo’s disclosure controls statements
22 are not adequately alleged to be false or misleading.

23 **b. Scienter**

24 Under the PSLRA, a plaintiff must “with respect to each act or omission . . . state
25 with particularity facts giving rise to a strong inference that the defendant acted with the
26 required state of mind.” 15 U.S.C. § 78u-4(b)(2)(A). A strong inference is “more than
27 merely plausible or reasonable—it must be cogent and at least as compelling as any
28 opposing inference of nonfraudulent intent.” *See Tellabs, Inc.*, 551 U.S. at 314; *see also*

1 *Reese v. Malone*, 747 F.3d 557, 569 (9th Cir. 2014), *overruled on other grounds by City*
2 *of Dearborn Heights Act 345 Police & Fire Ret. Sys. v. Align Tech., Inc.*, 856 F.3d 605
3 (9th Cir. 2017) (same). The relevant inquiry is “whether all of the facts alleged, taken
4 collectively, give rise to a strong inference of scienter, not whether any individual
5 allegation, scrutinized in isolation, meets that standard.” *Tellabs, Inc.*, 551 U.S. at 322–
6 24.

7 As to the meaning of “scienter,” the Ninth Circuit has held that a plaintiff’s
8 complaint must show that “the defendants made false or misleading statements either
9 intentionally or with deliberate recklessness.” *Zucco Partners, LLC v. Digimarc Corp.*,
10 552 F.3d 981, 990-91 (9th Cir. 2009), *as amended* (Feb. 10, 2009). “[F]acts showing
11 mere recklessness or a motive to commit fraud and [the] opportunity to do so” are
12 insufficient. *Id.* “To meet this pleading requirement, the complaint must contain
13 allegations of specific contemporaneous statements or conditions that demonstrate the
14 intentional or the deliberately reckless false or misleading nature of the statements when
15 made.” *Ronconi v. Larkin*, 253 F.3d 423, 432 (9th Cir. 2001). When an omission is at
16 issue, “the plaintiff must plead a highly unreasonable omission, involving not merely
17 simple, or even inexcusable negligence, but an extreme departure from the standards of
18 ordinary care, and which presents a danger of misleading buyers or sellers that is either
19 known to the defendant or is so obvious that the actor must have been aware of it.”
20 *Zucco*, 552 F.3d at 991.

21 In determining whether a claim satisfies this standard on a motion to dismiss, the
22 court first determines “whether any of the plaintiff’s allegations, standing alone, [are]
23 sufficient to create a strong inference of scienter.” *In re NVIDIA Corp. Sec. Litig.*, 768
24 F.3d 1046, 1056 (9th Cir. 2014). If no allegation alone is sufficient, the court must
25 engage in a “comparative assessment” that considers all the facts alleged in a complaint,
26 “collectively” and “holistically.” *Tellabs, Inc.*, 551 U.S. at 326–27; *see also In re*
27 *NVIDIA Corp. Sec. Litig.*, 768 F.3d at 1056 (The court must “consider the allegations
28 holistically to determine whether they create a strong inference of scienter taken

1 together.”). This analysis involves considering the plaintiff’s preferred inference of fraud
2 and plausible opposing inferences and nonculpable explanations for the defendant’s
3 conduct. *Id.*

4 Plaintiffs allege in the complaint that Defendants acted with scienter, as evidenced
5 by: (a) the confidential witness reports detailed in the complaint; (b) the Individual
6 Defendants’ close monitoring of Masimo’s sales and accounting metrics; (c) the
7 magnitude of the Sound United acquisition, the market’s reaction to the announcement of
8 the acquisition, and Defendants’ knowledge, throughout the Class Period, of severe
9 internal control issues at legacy Sound United; (d) Defendants’ reaction to, including
10 later dismissal of, one key financial employee for his refusal to sign a SOX sub-
11 certification; and (e) the fact that the Defendants’ statements concerned key aspects of the
12 Company’s business.⁷ (ECF No. 28 at ¶ 360.)

13 Defendants argue that Plaintiffs fail to plead scienter. They argue that: (a)
14 Defendants had no motive to commit fraud; (b) that the confidential witnesses do not
15 support a strong inference of scienter; (c) that Plaintiff’s allegations lack particularized
16 facts as to each Individual Defendant, (d) that allegations of scienter based on the focus
17 of the Sound United acquisition fail to meet pleading requirements; (e) that the core
18 operations doctrine is inapplicable; (f) and that the Sarbanes-Oxley certificate allegations
19 actually show a lack of scienter. (ECF No. 38-1 at 34-40.) Defendants argue that the
20 more compelling inference from Plaintiffs’ allegations are that Defendants acted in good
21 faith. (*Id.* at 40.)

22 Plaintiffs do not appear to argue that any allegation, standing alone, is sufficient to
23 plead scienter. *See In re NVIDIA Corp. Sec. Litig.*, 768 F.3d at 1056. Accordingly, they
24 must show that “consider[ed] holistically,” all of the allegations lead to “a strong
25

26
27 ⁷ In opposing Defendants’ motion to dismiss, Plaintiffs focus on Defendants’ access to
28 information, the confidential witness allegations, the specificity of Defendants’ false statements, and the
core operations doctrine. Accordingly, Plaintiffs have waived arguments for scienter not mentioned in
their motion. *See Image Tech. Serv., Inc. v. Eastman Kodak*, 903 F.2d 612, 615 n. 1 (9th Cir. 1990).

1 inference of scienter taken together. *Id.* First, Plaintiffs argue that “Defendants Kiani,
2 Young, Muhsin, and Kammerman had access to the undisclosed information that
3 rendered their statements misleading, thereby raising a strong inference of scienter.”
4 However, access to information alone is not enough to lead to an inference of scienter.
5 *See City of Dearborn Heights Act 345 Police & Fire Ret. Sys. v. Align Tech., Inc.*, 856
6 F.3d 605, 620 (9th Cir. 2017) (finding that allegations of “actual access to the disputed
7 information” may raise a strong inference of scienter, but that there is not a strong
8 inference of scienter when Defendant had “direct access” to disputed information but
9 there are no allegations that they “personally accessed” it).

10 Plaintiffs also allege that “Defendants Kiani, Young, and Muhsin also attended a
11 variety of regular meetings at Masimo where the weaknesses in internal controls, declines
12 in revenue, and the stalled status of the integration were discussed.” (ECF No. 42 at 35.)
13 However, the information alleged to be available to Defendants in these meetings did not
14 relate to the “plugs” or the state of the Sound United integration, the two areas that the
15 Court has found that Plaintiffs have alleged materially false or misleading. (*See* ECF No.
16 28 at ¶¶ 192-207.)

17 Plaintiffs also allege that the CW statements establish a strong inference of
18 scienter. Plaintiffs allege that Defendant Young was directly involved in the use of
19 “plugs” to balance Sound United’s books and to improve margins, creating an appearance
20 that Sound United was doing better than it was. According to CW-14, Defendant Young
21 would directly send him “topsides” or “plugs” to book as journal entries to make the
22 accounting work. (*Id.* at ¶ 161.) CW-14 described the “plug” as a cost of goods sold
23 credit that “juiced the margins,” “the motive of which was to make forecasted numbers
24 for legacy Sound United.” (*Id.*) CW-14 recalled that “Sound United was plugging as
25 much as \$9 million a month into the books as part of the closing process,” and that “the
26 manipulation of Sound United’s financial close numbers continued after the Sound
27 United acquisition.” (*Id.* at ¶ 162.) When CW-14 noted that “we weren’t going to make
28 the numbers,” then Defendant Young “redid capitalization based on a model he

1 developed,” and sent CW-14 “a \$4.2 million journal entry to add to topside” to balance
2 the books. (*Id.*) CW-14 described these adjustments as “11th hour topside entries,”
3 “always occurring a day or two before everything had to be final during his tenure.” (*Id.*
4 at ¶ 163.)

5 Plaintiffs also argue that “Defendants’ specific misstatements about matters they
6 purportedly knew regarding the SU acquisition and the performance of the Healthcare
7 Unit’s sales strongly support an inference of scienter.” (ECF No. 42 at 38.) However,
8 this vague assertion with no reference to any particular statement lacks the specificity
9 needed to plead scienter as required by the PSLRA. *See In re Rigel Pharmaceuticals,*
10 *Inc. Sec. Litig.*, 697 F.3d at 877 (Facts surrounding scienter required to be plead with
11 particularity).

12 Plaintiffs also argue the core operations doctrine supports a finding of scienter.
13 Under the core operations theory, “[a]llegations regarding management’s role in a
14 corporate structure and the importance of the corporate information about which
15 management made false or misleading statements may also create a strong inference of
16 scienter when made in conjunction with detailed and specific allegations about
17 management’s exposure to factual information within the company.” *S. Ferry LP, No. 2*
18 *v. Killinger*, 542 F.3d 776, 785 (9th Cir. 2008). Plaintiffs argue that “Masimo’s sales of
19 products through both its healthcare and non-healthcare segments were critical to the
20 Company’s continued success,” and thus management should know about “of stagnating
21 and falling demand for Masimo’s products and the ballooning inventory caused by SU’s
22 internal controls weaknesses and excessive discounting in the healthcare segment.” (ECF
23 No. 42 at 38.) However, these areas do not relate to the allegations that were sufficiently
24 plead—that accounting “plugs” were used that made future performance statements
25 misleading and that integration efforts were not as they seemed—and thus the core
26 operations theory cannot support scienter.

27 Defendants argue that Plaintiff’s “fraud theory makes no sense,” because Plaintiffs
28 do not allege a motive and did not show that Defendants made any stock sales during the

1 class period. While a motive, such as stock sales during the class period, can lead to a
2 strong inference of scienter, “the absence of a motive allegation is not fatal.” *Tellabs,*
3 *Inc.*, 551 U.S. at 325.

4 On balance, the Court finds that Plaintiffs have adequately plead scienter as to
5 Defendant Young. As alleged, Defendant Young was aware, and in fact directed, the use
6 of “plugs” to balance Sound United’s books, thus showing a strong inference of scienter.
7 However, Plaintiffs have failed to plead scienter as to any of the other Individual
8 Defendants, as they are not alleged with particularity to have made false or misleading
9 statements either intentionally or with deliberate recklessness.⁸

10 **c. Conclusion**

11 As Plaintiffs have alleged at least some of the challenged statements are materially
12 misleading or false and have adequately alleged scienter as to Defendants Young and
13 Masimo, the Court declines to dismiss the claim for a violation of § 10(b) of the
14 Exchange Act and Rule 10b-5. However, the Court dismisses the claim for a violation of
15 § 10(b) as to the other Individual Defendants.

16 **2. Violation of § 20(a) of the Exchange Act**

17 Congress has established liability in § 20(a) for “[e]very person who, directly or
18 indirectly, controls any person liable” for violations of the securities laws. 15 U.S.C. §
19 78t(a). To prove a prima facie case under Section 20(a), a plaintiff must prove: (1) “a
20 primary violation of federal securities law;” and (2) “that the defendant exercised actual
21 power or control over the primary violator.” *See Howard v. Everex Sys., Inc.*, 228 F.3d
22 1057, 1065 (9th Cir. 2000).

23 Defendants argue that “[b]ecause Plaintiffs’ Section 10(b) claim fails, they cannot
24 establish control-person liability under Section 20(a).” (ECF No. 38-1 at 40.) However,
25

26 ⁸ Defendants argue that Plaintiffs have not shown that Masimo acted with scienter because they
27 failed to show any of the Individual Defendants acted with scienter. (ECF No. 38-1 at 40 n.4.) As this
28 Court holds that Plaintiffs have adequately alleged Defendant Young acted with scienter, the Court also
holds that Plaintiffs have adequately alleged that Masimo acted with scienter.


1 this Court finds that Plaintiffs have alleged a Section 10(b) claim as to Defendants Young
2 and Masimo. Accordingly, the Court declines to dismiss the Section 20(a) claim.

3 **V. CONCLUSION**

4 For the reasons stated above, Defendants' motion to dismiss is GRANTED IN
5 PART and DENIED IN PART. Leave to amend is granted. Plaintiffs must file an
6 amended complaint, if at all, no later than December 6, 2024.

7 **IT IS SO ORDERED.**

8 Dated: November 5, 2024

9 
10 Hon. M. James Lorenz
11 United States District Judge
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28